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ABSTRACT 
THE ROLE OF TUMOR STROMA AND CANCER ASSOCIATED FIBROBLASTS 
IN TUMOR GROWTH THROUGH CYTOKINES 
 BİRAN MUSUL  
M.Sc. Thesis, July 2018 
Thesis Supervisor: Prof. Devrim Gözüaçık 
Keywords: Tumor stroma, cancer associated fibroblasts, cytokine, tumor growth. 
Development of a tumor is a parallel event with the expansion of tumor microenvironment. 
Although most of the treatment strategies target only malignant cells, advanced understanding of 
the stromal contribution in cancer progression may enhance our knowledge and allow us to develop 
better treatments. Tumor stroma consists of different types of cells such as a heterogenous 
population of fibroblasts, immune cells, pericytes, endothelial cells and other noncellular 
components like extracellular matrix. Studies have shown that the interaction between malignant 
cells and stromal components through cytokine secretion has a crucial role in cancer progression. 
Moreover, these stromal cells and components can be recruited, manipulated, and altered by cancer 
cells to provide a permissive environment rather than a defensive one. One of the major components 
of tumor stroma is cancer associated fibroblasts (CAFs). In normal tissues, fibroblasts are found in 
a quiescent state and they become activated upon stimulations such as wound healing and fibrosis. 
Their activation is a reversible process and most of the activated fibroblasts are removed by 
apoptosis after wound healing. However, recent studies showed that CAFs differ from normal 
activated fibroblasts in terms of proliferation, migratory capacity, and secretory phenotype. In vitro 
and animal studies reveal that they enhance tumor growth and progression.  
In this study, we present that CAFs can enhance the growth of MCF7 and T47D breast cancer cells 
in vitro when they are co-cultured. Our co-culture experiments showed that this tumor promoting 
effect of CAFs is not dependent on cell-to-cell contact and it is caused by their crosstalk through 
cytokine secretion. We found that Activin A, Interleukin 5 and Angiogenin are present in higher 
levels in the cell culture media of CAF co-culture and similarly their expression in human breast 
cancer tumor samples are increased. Moreover, we showed that tumor growth due to CAFs can be 
reversed using specific neutralizing antibodies. Additionally, recombinantly produced cytokines 
were able to enhance the growth of MCF7 and T47D cells without the presence of CAFs in the 
culture. Therefore, we propose that CAFs induce tumor growth by their interaction with malignant 
cells through the secretion of specific cytokines and targeting this interaction can be developed as a 
new strategy in cancer treatment.  
 
 
 
 
 
v 
 
ÖZET 
TÜMÖR STROMASI VE KANSERLE İLİŞKİLİ FİBROBLASTLARIN 
SİTOKİNLER ARACILIĞI İLE TÜMÖR BÜYÜMESİNDEKİ ROLÜ 
 
BİRAN MUSUL 
Master Tezi, Temmuz 2018 
Tez Danışmanı: Prof. Devrim Gözüaçık 
Anahtar Kelimeler: Tümör stroması, kanserle ilişkili fibroblastlar, sitokin, tümör 
büyümesi 
Bir tümörün gelişmesi, tümörün mikroçevresinin genişlemesiyle paralel gerçekleşen bir olaydır. 
Çoğu tedavi stratejisi kötü huylu hücreleri hedeflemekte olsa da, kanser gelişimindeki stroma 
katkısını anlamak, bilgimizi genişletip daha iyi tedaviler geliştirmemize yardımcı olabilir. Heterojen 
fibroblast popülasyonu, bağışıklık sistemi hücreleri, perisitler ve endotelyal hücreler gibi farklı 
hücre türlerine ek olarak ektrasellüler matriks gibi hücresel olmayan bileşenler tümör stromasını 
oluştururlar. Çalışmalar göstermiştir ki, sitokinler üzerinden gerçekleşen, kötü huylu hücrelerle 
stroma bileşenleri arasındaki etkileşimin, kanser gelişimi üzerinde çok önemli bir rolü 
bulunmaktadır. Dahası, bu stromal hücreler, kanser hücreleri tarafından düzenlenerek, yönetilerek 
ve değiştirilerek daha elverişli bir çevre oluşturmaktadır. Tümör stromasının en büyük 
bileşenlerinden bir tanesi kanserle ilişkili fibroblastlardır. Normal dokularda, fibroblastlar sessiz 
durumda bulunurlar ve yara iyileşmesi ve fibröz gibi uyaranlarla aktif hale gelirler. Aktivasyonları 
geri çevirilebilir bir işlemdir ve çoğu aktif fibroblast yara iyileşmesi sonrasında apoptoz ile 
uzaklaştırılırlar. Fakat son çalışmalar göstermiştir ki, kanserle ilişkili fibroblastlar çoğalma, hareket 
kabiliyeti ve salgılama fenotipleri açısından normal aktif fibroblastlardan farklılaşmaktadır. İn vitro 
ve hayvan deneyleri, bu hücrelerin tümör büyümesi ve gelişmesini arttırdığını ortaya çıkarmıştır.  
Biz bu çalışmada, birlikte kültür edildikleri şartlarda, kanserle ilişkili fibroblastların, MCF7 and 
T47D meme kanseri hücrelerinin in vitro ortamda büyümelerini arttırdığını sunmaktayız. Bizim 
birlikte kültür deneylerimiz göstermiştir ki, kanserle ilişkili fibroblastların bu tümör büyütücü etkisi 
hücrelerin temasından çok, sitokinler üzerinden gerçekleşen karşılıklı iletişim sebebiyle 
gerçekleşmektedir. Kanserle ilişkili hücrelerin birlikte kültürlerinde Activin A, Interleukin 5 ve 
Angiogenin faktörlerinin daha yüksek seviyelerde bulunduğunu ve benzer şekilde meme kanseri 
hastalarının tümör örneklerinde de bu faktörlerin ifadelerinin yükselmiş olduğunu bulduk. Dahası, 
özel nötralize antikorların kullanımı ile kanserle ilişkili hücre kaynaklı tümör büyümesini tersine 
çevirebileceğimizi gösterdik. Ek olarak, rekombinant olarak üretilen sitokinler, MCF7 ve T47D 
hücrelerinin büyümesini, kanserle ilişkili fibroblastların varlığı bulunmasa da arttırmıştır. Bu 
sebeple, kanserle ilişkili fibroblastların tümör büyümesini sitokinler aracılığıyla gerçekleştirdiklerini 
ve bu etkileşimin hedeflenerek yeni kanser tedavi stratejilerinin geliştirilebileceğini öne 
sürmekteyiz.  
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1.  INTRODUCTION 
1.1 Cancer and Tumor Microenvironment 
Despite extensive cancer research, advanced molecular biology techniques, 
medical treatments, and accumulating knowledge for many years there is still a gap 
between cancer biology in the experimental and clinical outcomes. This is mostly because 
until recent years cancer studies have mostly centered upon only malignant cells. 
However, today, researchers came to realization and it is a widely accepted that tumor 
microenvironment and the interactions among its components have a crucial role in 
cancer progression as well as cancer treatments. 
Tumors do not only consist of uncontrollably dividing cells, but they are also 
composed of several different cell types including endothelial and mesenchymal cells, 
immune cells, fibroblasts as well as other non-cellular constituents such as extracellular 
matrix (ECM). In addition to this, researchers identified that malignant cells can recruit 
and manipulate these cells in tumor microenvironment, modify extracellular matrix and 
change the environment in a way that all these changes support tumor formation, 
progression, invasion, and metastasis. Although “The Seed and Soil Hypothesis” was first 
proposed by Stephen Paget in 1889 [1] and it has been more than hundred years now, we 
recently started to comprehend the important role of this complex interaction between the 
tumor cells and the tumor stroma. Today we know that to create a permissive environment 
rather than a defensive one, cancer cells can transform and alter the tumor stroma and the 
connective tissue in which they reside [2]. Additionally, one of the key features of 
malignant cancer cells is that they are capable of invasion and metastasis [3,4]. For this 
reason, the communication and interaction between cancer cells and other constituents of 
tumor stroma have gained an essential role in the understanding and the prevention of 
cancer progression [4-9]. 
1.2 Tumor Stroma 
During cancer progression, host tissue stroma provides the maintenance of both 
normal epithelial tissues and malignant counterparts. Other than cancer cells, the tumor 
stroma mainly consists of basement membrane, extracellular matrix consisting of 
structural proteins like collagen, elastin, fibrilin, and proteoglycans, vasculature, and 
other nonmalignant cells such as fibroblasts, distinctive mesenchymal cell types, innate 
and adaptive immune cells, endothelial cells, and pericytes (Figure 1.1).  
2 
 
Angiogenesis and newly formed vasculature is also essential tumor formation and 
survival. Initiation of angiogenesis requires degradation of the basement membrane (BM) 
induced by matrix metalloproteinases (MMPs), formation of new endothelial cells and 
pericyte attachment. Collective work of other components of stromal compartments also 
has a crucial role in orchestrating these events by the secretion of various ECM molecules 
and growth factors such as fibroblast growth factor (FGF2), transforming growth factor 
(TGF-beta), and vascular endothelial growth factor (VEGF) [9]. 
 
 
Figure 1.1 Heterogenous population and components of tumor stroma [17]. 
 
1.2.1 From Normal Stroma to Tumor Stroma 
The normal stroma has a crucial role in providing epithelial tissue maintenance 
and integrity. It also sustains tissue homeostasis by the collaborative work of several cell 
types that it contains. These stromal cells have a continuous and constant crosstalk with 
normal epithelial cells, and this crosstalk is mainly mediated by either direct cell-to-cell 
contacts or secreted factors (Figure 1.2). Since these interactions are essential for tissue 
homeostasis, even the smallest changes in one part of this network may cause dramatic 
alterations in the whole system. 
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To allow a permissive and supportive environment for the cancer cells, transition 
from normal stroma to tumor stroma is achieved by the consequent changes in the host 
stromal compartments as a result of the formation of malignant cells and cancer 
development by the accumulation of genetic and epigenetic alterations [11]. During the 
initiation and early stages of tumor formation, progression and invasion, the basement 
membrane structure is disrupted, tissue stroma (containing fibroblasts, inflammatory 
infiltrates, capillaries) is altered, and tumor cells come to a direct contact with stromal 
compartments. These modifications also determine cytokine interactions between tumor 
cells and fibroblasts [12]. As a result of all these cancer-induced alterations and 
modifications in tissue stroma, it becomes a contribution to cancer development, invasion 
and metastasis [13].  
 
 
Figure 1.2 Continuous crosstalk between epithelial cells/cancer cells and normal 
stroma/tumor stroma. 
Animal studies have shown that activation of stroma through various factors 
provides oncogenic signals and consequently facilitated tumorigenesis [14]. One of the 
most dramatic changes happen in ECM. Normal stroma in most organs consists of a low 
number of fibroblasts associated with ECM production whereas the activated stroma 
contains more ECM producing fibroblasts and as a result more ECM production [15]. 
This stromal expansion with the increased number of fibroblasts and densely deposited 
ECM is called desmoplastic reaction (morphologically desmoplasia) [16]. This reaction 
was initially considered as a defense mechanism against tumor growth, however, quite 
oppositely, researchers have shown that it takes parts in angiogenesis, migration, 
invasion, and metastasis in established tumors [17]. Other studies showed that 
collaboration of fibroblasts and cancer cells can enhance tissue growth and cancer 
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progression by both the secretion and degradation of ECM components inside the tumor 
stroma [18].   
1.2.2 Angiogenic and profibrotic growth factors derived from cancer cells 
Cancer cells have been shown to have a role in the determination of the volume 
and composition of tumor stroma by secreting several profibrotic growth factors such as 
TGF-beta, FGF2, and platelet-derived growth factor (PDGF) as they mediate fibroblast 
activation and tissue fibrosis [5]. Additionally, angiogenic factors like VEGF family, has 
a crucial role in activated stroma [19]. Although VEGF family proteins are mostly 
secreted by fibroblasts and inflammatory cells, malignant cells were also shown to release 
VEGF [20]. VEGF is known to increase neovascularization and vascular permeability 
which results in extravasation of plasma proteins. Then, fibroblasts, inflammatory and 
endothelial cells are attracted to these plasma proteins such as fibrin [21]. These cells, in 
return, enhance tumor fibrosis and angiogenesis. 
1.3 Fibroblasts and their activation 
Fibroblasts have quite distinct characteristics based on the tissue from which they 
derive. They were identified nearly hundred years ago, and gene analysis studies have 
shown that they have specific roles [22]. Normal fibroblasts are found in quiescent state 
embedded in ECM in tissue homeostasis and they interact with their neighbors through 
cell receptors such as integrins [17]. However, certain signals such as wound healing and 
fibrosis can stimulate fibroblasts to activate. Upon this activation, they are called 
myofibroblasts, they undergo some morphological and functional differentiation, they 
become capable of producing and secreting relevant mediators such as growth factors, 
cytokines, and immune signals [23]. However, this activation is reversible and after the 
signal that caused activation disappeared, like wound healing is completed, these 
activated fibroblasts either go back to their quiescent state or they are removed from the 
tissue by apoptosis [24]. This process considered to be different in cancers. One of the 
reasons why scientists define cancer as “a wound that never heals” is that activated 
fibroblasts stay in their activated state and they are not removed by apoptosis as in wound 
healing. Instead of this reversible process, they become prominent actors of 
carcinogenesis.  
In cancer, these irreversibly activated fibroblasts are called cancer associated 
fibroblasts (CAFs). Like other activated fibroblasts, they are thought to reside in a highly 
heterogeneous population. Although local normal fibroblasts are considered to be the 
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progenitors of CAFs, studies have shown that they can also be derived from pericytes, 
muscle cells, and mesenchymal cells [25]. Studies have also showed that CAFs differ 
from normal fibroblasts by epigenetic and possibly some genetic changes [26]. CAFs are 
usually recognized by increased expression of alpha-smooth muscle actin (α-SMA) but 
other CAF markers such as fibroblast-specific protein 1 (FSP 1), fibroblast activation 
protein (FAP), and vimentin are also being used to define them [27].  
In response to formation of cancer cells and tumorigenesis, normal fibroblasts get 
activated by secreted molecules such as TGF-β, MCP 1, and MMPs which modify ECM. 
Although several studies proposed an inhibitory effect of normal fibroblasts to cancer 
progression, cancer promoting role of CAFs is widely accepted. As a matter of fact, in 
breast cancers, 80% of this heterogeneous fibroblast population is considered to be CAFs 
and have activated phenotype [28].   
1.3.1 CAFs as positive regulators of cancer 
Cancer associated fibroblasts that are isolated from human tumors differ from 
normal fibroblasts from healthy tissue in many ways such as increased proliferative and 
migratory capacity, autocrine signaling, and increased secretory phenotype (Figure 1.3) 
[29]. However, interestingly, these changes that are observed in CAFs and that could be 
because of epigenetic changes which caused their activation, are not found in normal 
activated fibroblasts [30]. Moreover, many co-culture experiments have shown that CAFs 
have an ability to promote tumorigenesis whereas NAFs lack this ability []. Similarly, it 
is also observed that CAFs can induce invasion of cancer cells [31]. All these imply that, 
differently from normal fibroblast activation, CAFs have distinct and crucial roles in 
cancer development. 
In addition, a part of the tumor promoting effects of CAFs is thought to be their 
ability to induce angiogenesis by secreting stromal cell derived factor 1 (SDF1) and 
recruiting endothelial cells. Similarly, CAFs contribute to tumorigenesis by secreting 
other modulators such as heat shock factor 1 (HSF1) that can complement this program 
in cancer cells and Yes-associated protein 1 (YAP1) that can alter ECM structure and 
increase cancer cell invasion [32]. Moreover, deregulations in Notch and p53 signaling 
in cancer associated fibroblasts enhance their proliferative capacity and makes cancer 
development more complex and difficult to understand [30,32]. However, to understand 
all these pathways, deregulations, and alterations more work is needed.  
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Figure 1.3 CAFs secretory phenotype and their cross-talk with neighboring cells [17]. 
 
1.3.2 CAFs and cancer stem cell niche 
The generation, maintenance and promotion of cancer stem cells and cancer stem 
cell niche may be elicited by the cooperative work CAFs and cancer cells in remodeling 
ECM. Stromal remodeling and maintenance of cancer stem cell niche by WNT signaling 
may be regulated by fibroblasts which express Periostin (POSTN) [35]. Studies have 
shown elevated WNT signaling in colon cancer stem cells which are near CAFs 
implicating that the role of CAF-derived HGF in the formation of cancer stem cell niche. 
Similarly, in lung cancer, cancer stem cells have been shown to induce fibroblast 
activation by Thrombospondin 2 (THBS2) expression which in turn enhance metastasis. 
These signaling events between cancer stem cells and fibroblasts, activates fibroblast-
derived IGF2 and IGF1 receptor signaling in cancer stem cells which induces the 
activation of Nanog expression and stemness in cancer cells [36]. 
 
1.3.3 CAFs in metastasis 
CAFs are considered as one of the important members of metastatic growth at a 
secondary site. Release of mediators such as growth factors and cytokines into the 
circulation by CAFs from the primary site may directly or indirectly support metastasis 
and growth and cancer cells may gain invasive characteristics at a distant site [37,38]. 
ECM remodeling role of CAFs at the primary site may enhance invasion and CAFs may 
form ECM tracks to guide cancer cells. Studies demonstrated that metastasis associated 
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fibroblasts (MAFs) mediate breast cancer metastasis to the lung by expression of 
Tenascin C and VEGF-A [39]. In addition, CAFs induces angiogenesis in melanoma 
metastasis [40]. Similarly, IL-11 secretion from CAFs that are stimulated by TGF-β1 
increases the survival and organ colonization in colorectal cancers. Researchers also 
reported that CAFs induce intravasation and metastasis colorectal cancer cells via STC1 
secretion [41]. In animal studies, Fsp1-knockout mice presented impaired fibroblast 
mobility and reduced metastasis [42].  
MAFs may emerge as a result of distant tissue fibroblast activation by metastatic 
cancer cells or they may be recruited from other tumor sites. Possibility of multiple origins 
may contribute to various functional properties.  
1.4 Cytokines  
Cytokines is a broad definition of small proteins (5-30 kDa) that have important 
roles in cell signaling and they affect the behavior of neighboring cells around them. They 
are involved in autocrine and paracrine signaling as modulating agents. Cytokines can be 
grouped as chemokines, lymphokines, interleukins and interferons. Despite some overlap, 
generally, growth factors are not considered as cytokines. They can be produces and 
secreted by a range of cells such as immune cells, endothelial cells, and fibroblasts [43]. 
Cytokines act through receptors and regulate cell-based responses. They can 
modulate the growth and maturation of certain populations of cells in health and diseases 
such as infection, inflammation, cancer, and reproduction [44]. For example, oxidative 
stress induces several inflammatory cytokines [45,46] and they themselves activate the 
secretion of other cytokines [47-49].  
Cytokines circulate in picomolar concentrations and the variability in cellular 
sources differentiates them from hormones [50]. Each cytokine has a cell surface receptor 
and binding induces a subsequent intracellular signaling which leads to alterations in 
cellular function. These alterations may include deregulation of gene expressions, cellular 
response to a certain stimulus, and growth. The effect of a cytokine depends on the 
cytokine, its abundance, matching receptor, and downstream signaling.  
During embryogenesis and immune responses, cytokines have a crucial role [51-
53]. However, they can be dysregulated under certain pathologic conditions and they are 
linked to many diseases such as Alzheimer’s disease [54] and cancer [55]. Especially, in 
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cancer which threatens normal tissue integrity and homeostasis, studies showed disrupted 
interactions and feedbacks of secreted cytokines [56].  
Using recombinant DNA technology, some recombinant cytokines have been 
developed to be used as drugs [57]. For example; Erythropoietin, used to treat anemia; 
Interferon alpha and beta, used to treat hepatitis C and multiple sclerosis; Interleukin 2; 
used to treat cancer.  
1.5 Cytokines and Cancer 
Cytokines that are produced in tumor stroma have an important role in cancer progression. 
Some cytokines that are secreted in response to inflammation or immunity can inhibit cancer 
development whereas some cytokines can promote tumor growth, invasion and metastasis (Table 
1.1). In addition, therapies based on stromal cytokines, their composition and effects on both cancer 
and stromal cells, have a potential to be used as effective treatment methods (Table 1.2).  
Table 1.1 Cytokines and their roles in cancer formation 
 
 
 
 
 
 
 
 
IL-1 Tumor invasion and angiogenesis
IL-6 Chemically induced lymphomas
IL-12 Inhibition of chemical carcinogenesis
IL-15 NK cell leukaemias
IFN-γ Inhibition of lymphomas
M-CSF Breast cancer invasion
GM-CSF Inhibition of lymphomas and carcinomas
TNF-α Chemically-induced skin cancer
MIF Inhibition of p53
TGF-β Inhibition of colon carcinomas
Fas-Fas ligand Inhibition of lymphomagenesis
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Table 1.2 Cytokines as cancer therapy 
 
 
In this study, we present that CAFs can enhance the growth of MCF7 and T47D breast 
cancer cells in vitro when they are co-cultured. Our co-culture experiments showed that this tumor 
promoting effect of CAFs is not dependent on cell-to-cell contact and it is caused by their crosstalk 
through cytokine secretion. We found that Activin A, Interleukin 5 and Angiogenin are present in 
higher levels in the cell culture media of CAF co-culture and similarly their expression in human 
breast cancer tumor samples are increased. Moreover, we showed that tumor growth due to CAFs 
can be reversed using specific neutralizing antibodies. Additionally, recombinantly produced 
cytokines were able to enhance the growth of MCF7 and T47D cells without the presence of CAFs 
in the culture. Therefore, we propose that CAFs induce tumor growth by their interaction with 
malignant cells through the secretion of specific cytokines and targeting this interaction can be 
developed as a new strategy in cancer treatment. 
  
IL-2 Enhances NK cell and CD8 T cell function; increases vascular permeabilty
IL-3 Enhances cancer antigen presentation
IL-4 Enhances eosinophil function and T-cell activation
IL-6
Enhances T-cell and B-cell function; inhibition of IL-6 reduces 
lymphoproliferation
IL-7 Enhances T-cell function
IL-10 Inhibits cancer antigen presentation
IL-12 Enhances Th1 immunity and cytotoxicity; anhibits angiogensis
IL-13 Inhibits cytotoxicity against viral neoplasms
IL-15 Enhances cytotoxicity
IL-18 Enhances Th1 immunity and cytotoxicity; inhibits angiogenesis
M-CSF Enhances macrophage function
GM-CSF Enhances cancer antigen presentation
IFN-α Enhances cancer antigen presentation and cytotoxicity
IFN-γ Enhances cancer antigen presentation and cytotoxicity
TNF-α Induces tumor-cell apoptosis; activates andothelium and granulocytes
TRAIL Induces tumor-cell apoptosis
FLT3 ligand Stimulates dendritic-cell and NK-cell function
Lymphotactin Enhances T-cell recruitment
TGF-β Inhibits T-cell effector function
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2. MATERIALS AND METHODS 
2.1 Isolation of fibroblasts and CAFs from human breast tissue samples 
After receiving tissue samples in sterile DMEM media, they were washed with 
PBS. Then, they were minced into small pieces and treated with Liberase TL (Roche, 
05401020001) at 37 oC for 1-2 hours depending on the size of the sample. Samples were 
vortex every 30 minutes allowing a homogeneous mixture. After we obtained single cell 
suspensions, we washed the samples with DMEM and PBS and seeded them on 6-well 
culture plates. 
 
2.2 Cell culture and transfection 
MCF7, T47D, HEK293T, fibroblasts and CAFs were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Biological Industries, #BI01-050-1A). Culture media 
was supplemented with 10% (v/v) fetal bovine serum (FBS, PAN, #P30-3302) (3%FBS 
supplementation for co-culture and other experiments), antibiotics 
(Penicillin/streptomycin, Biological Industries, #BI03-031-1B) and L-Glutamine 
(Biological Industries, #BI03-020-1B) Cells were stored in 5% CO2 humidified incubator 
at 37°C. HEK293T cells were transiently transfected with calcium phosphate transfection 
method following the standard protocols. 
 
2.3 Immunoblotting and antibodies 
Cells were lysed at indicated time points in RIPA buffer (50 mM TRIS-HCl pH 
7.4, 150 mM NaCl, 1% NP40, 0.25% Na-deoxycholate) supplemented with a complete 
protease inhibitor cocktail (Roche, 04-693-131-001) and 1 mM phenylmethylsulfonyl 
fluoride (PMSF, Sigma-Aldrich, P7626). Protein extracts (30 µg per well) were separated 
using 10-15% SDS-polyacrylamide gels (SDS-PAGE), and then transferred onto 
nitrocellulose membranes (Millipore, #IPVH00010). Membranes were blocked in 5% 
nonfat milk (Applichem, #A0830) in PBST (3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 
mM KCl, 135 mM NaCl, and 0.05% Tween 20, pH 7.4) for 1 h and then incubated with 
primary antibodies in a 3% BSA PBST solution: anti-Flag (Sigma, A494842), anti-LC3 
(CST, #2775S) and anti-β-ACTIN (Sigma-Aldrich, A5441) antibody as loading control. 
Following PBST washes, membranes were incubated with horseradish peroxidase 
(HRP)-coupled secondary anti-mouse (Jackson Immunoresearch laboratories, 
#115035003) or anti-rabbit antibodies (Jackson Immunoresearch Laboratories, 
#111035144). Band intensities were quantified using the ImageJ software. 
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2.4 RNA isolation and qRT-PCR analyses 
Total RNA was extracted using TRIzol reagent (Sigma-Aldrich, #T9424) 
according to the manufacturer’s instructions. cDNA was reverse transcribed from DNase-
treated total RNA using M-MuLV reverse transcriptase (Fermentas, #EP0351), and 
random hexamers (Invitrogen, #48190-011).  
For single-step qRT-PCR reaction, SYBR Green Quantitative RT-PCR kit (Roche, #04-
913-914-001) and LightCycler 480 (Roche) were used. To activate the SYBR green, an 
initial cycle of 95°C, 10 min was performed followed by PCR reactions: 40 cycles of 
95°C for 15 sec. and 60°C for 1 min. Then a thermal denaturation protocol was used to 
generate the dissociation curves for the verification of amplification specificity (a single 
cycle of 95°C for 60 sec., 55°C for 60 sec. and 80 cycles of 55°C for 10 sec). Changes in 
mRNA levels were quantified with the 2-∆∆CT method and normalized to GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) mRNA.  
 
2.5 Immunofluorescence Analyses 
Cells were cultured on coverslides and fixed in ice-cold 4% 
paraformaldehyde/PBS. For indirect immunostaining experiments, following fixation, 
cells were permeabilized in PBS containing 0.1% BSA (Sigma, #A4503) and 0.1% 
saponin (Sigma, #84510). As primary antibodies, anti-αSMA (Abcam, ab5694), anti-
Vimentin (Abcam, ab92547) were used. Anti-mouse Alexa Fluor 488 (Invitrogen, 
#A32723) and anti-rabbit Alexa Fluor 488 (Invitrogen, #A11034) were used as secondary 
antibodies. Coverslides were mounted onto glass slides, and samples were analyzed using 
Carl Zeiss LSM 710 confocal microscope (Zeiss, Germany). 
 
2.6 Flow cytometry analysis 
To confirm growth analyses, MCF7-RFP cells were co-cultured with fibroblasts 
and CAFs. At the end of co-culture, cells were washed 2 times with PBS and trypsinized. 
Cells were fixed by using ice-cold 70% ethanol and then resuspended in PBS. RFP 
positive cells were detected using BD FACSCanto™ instrument and analyzed using Flow 
Jo software (Tree Star Inc). A minimum of 10000 events per sample corresponded to 
gated population were collected, and cellular debris was not counted.  
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2.7 Cytokine Array 
 72 hours after fibroblast and CAF co-cultures, conditioned media used to detect 
differentially secreted cytokines. For this purpose, we used Human Cytokine Array 
C4000 (RayBiotech, AAH-CYT-4000) and followed manufacturer’s instructions. 
 
2.8 Luciferase Activity Analysis 
 MCF7 and T47D cells which express luciferase were treated with Chris Buffer at 
37 oC for 5 minutes. After that cell lysates were collected and centrifuged for 5 minutes 
at 1000 g. Supernatant was kept on ice and later mixed with homemade luciferase reagent 
to detect luciferase activity with luminometric measurement.  
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3. RESULTS 
3.1 Characterization of Fibroblasts and CAFs isolated from tissue samples 
CAFs are key components of tumor stroma and previous studies identified their 
tumor promoting capacity compared to fibroblasts and NAFs. In addition, in breast 
cancers, around 80% of the heterogeneous fibroblast population inside the tumor stroma 
is shown to be CAFs. One of the distinctive characteristics of CAFs is their elevated 
expression level of α-SMA and Vimentin, and the formation of stress fibers. Upon 
receiving healthy and tumor breast tissue samples in sterile conditions, they were minced 
into smaller pieces and treated with Liberase TL to obtain single cell suspensions. After 
that, these primary cell suspensions were cultured in DMEM (10% FBS) until we 
obtained normal fibroblasts and CAFs in cell culture conditions. Characterization of 
fibroblasts and CAFs was done using immunofluorescence staining using α-SMA and 
Vimentin antibodies. Confocal microscopy images showed the distinct morphological 
changes, increased level of expression of both α-SMA and Vimentin as well as the 
formation of stress fibers in CAFs which were isolated from tumor samples compared to 
fibroblasts from healthy breast tissue sample of the same patient (Figure 3.1). 
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Figure 3.1 Characterization of fibroblasts and CAFs. α-SMA and Vimentin stainings and 
confocal microscopy analyses showed morphological changes, increased expression 
levels of both proteins and the formation of stress fibers in CAFs (below) compared to 
fibroblasts (above) from the healthy tissue samples of the same patient.  
  
3.2 Differential effects of fibroblasts and CAFs on cancer cell growth in vitro 
Although CAFs are similar to normal activated fibroblasts, their roles in 
tumorigenesis and cancer progression are not fully identified. However, several studies 
have shown their pro-tumorigenic roles and demonstrated that they enhance tumor 
growth. To see the effect of CAFs in cancer cell proliferation, we co-cultured MCF7 and 
T47D breast cancer cells with either fibroblasts or CAFs. MCF7 and T47D alone without 
the presence of fibroblasts or CAFs were used as control and after 72 hours of co-culture 
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in DMEM (3% FBS) their growths were compared. In the first part, we co-cultured 
fibroblasts and CAFs together with either MCF7 or T47D cells which stably expressing 
luciferase. After 72 hours, cells were lysed using Chris buffer and cell lysates were used 
to measure their luciferase activity using luminometric analyses. Both intensities of 
fibroblast and CAF co-cultures were normalized to MCF7 and T47D alone conditions. 
As a result of luciferase activity assays, co-culture of cancer cells with CAFs showed 
significantly increased proliferation compared to both control and fibroblast co-culture 
conditions (Figure 3.2A and 3.2B). Similarly, we confirmed these results by using 
microscopy images (Figure 3.2C) and FACS analysis (Figure 3.3D) of co-cultures of 
fibroblasts and CAFs with MCF7 cells which stably express RFP protein.  
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Figure 3.2 Differential effects of fibroblasts and CAFs on cancer cell growth in vitro. A. 
Relative luciferase activity of MCF7 cells after 72 hours of either growing alone or co-
culture with fibroblasts or CAFs (n=6, p<0.05). B. Relative luciferase activity of T47D 
cells after 72 hours of either growing alone or co-culture with fibroblasts or CAFs (n=3, 
p<0.05). C. Microscopy images of RFP expressing MCF7 cells after 72 hours of co-
culture with fibroblasts or CAFs. D. Quantification of relative RFP intensities of 
fibroblast and CAF co-cultures of MCF7-RFP cells in FACS analysis.  
 
3.3 Analysis of secreted factors in fibroblast and CAF co-cultures 
To determine whether tumor promoting effect of CAFs is dependent on cell-to-
cell contact, we changed the co-culture conditions and provided a physical distance 
between fibroblasts/CAFs and cancer cells. For this purpose, after seeding either 
fibroblasts or CAFs onto cell culture plates, MCF7 cells were seeded on inserts which has 
pores (0.4µm) that will allow the passage of secreted factors but prevent a direct cellular 
contact (Figure 3.4A). Under these conditions, after 72 hours of co-culture or culturing 
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MCF7 cells alone, cancer cells were collected to measure their luciferase activity which 
reflect their proliferation. Relative luciferase activities in each group were measured and 
we observed a similar result that CAFs promoted the growth of cancer cells more than 
fibroblast co-culture and cancer cells alone conditions (Figure 3.4B). This result indicated 
that growth promoting effect of CAFs should be due to secreted factors such as cytokines, 
lymphokines, and/or growth factors. To determine which factors were secreted 
differentially in fibroblast and CAF co-culture conditions, co-culture media were 
collected and analyzed using RayBiotech cytokine array (Figure 3.3). As a result, we were 
able to identify three cytokines (Activin A, IL-5, and Angiogenin) which were secreted 
in significantly higher amounts (cutoff=1.5 fold) in CAF co-cultures compared to 
fibroblast co-cultures (Figure 3.4C and 3.4D).  
 
Figure 3.3 Schematic representation of co-culture media collection and RayBiotech 
cytokine array. 
 
18 
 
 
Figure 3.4 Determination of differentially secreted factors in fibroblast and CAF co-
cultures. A. Schematic representation of co-culture condition using inserts. B. Relative 
luciferase activities of MCF7 alone, fibroblast co-culture, and CAF co-culture after 72 
hours using inserts. C. Representative image of two independent experiments of 
RayBiotech cytokine array results (1: Activin A, 2: IL-5, 3: Angiogenin). D. 
Quantification of cytokine array results. This graph represents the average of relative 
intensities of three cytokines that were 1.5-fold or higher in two independent experiments. 
 
3.3.1 Determination of the possible sources of cytokine secretion 
To determine which cells predominantly secrete these three factors, MCF7 cells, 
fibroblasts, and CAFs were collected before and after co-culture of 72 hours using inserts. 
Total RNA from these cells were extracted using Trizol reagent and cDNAs were 
amplified using specific primers for Activin A, IL-5 and Angiogenin. qRT-PCR results 
demonstrated that CAFs are more likely to be the main sources of Activin A secretion 
due to the higher expression level compared to MCF7 cells and fibroblasts (Figure 3.5A) 
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whereas IL5 was secreted mostly by MCF7 cells with a little contribution of CAFs (Figure 
3.5C). Our result also showed that both MCF7 cells and stromal cells contribute in 
Angiogenin secretion (Figure 3.5E). Moreover, our result also implies that the target of 
Activin A secreted from CAFs is cancer cells since MCF7 cells had higher expression 
level of Activin A receptor (Figure 3.5B) and the target of IL5 which was mostly secreted 
by MCF7 cells was stromal cells (Figure 3.5D) due to higher expression level of IL5RA. 
 
 
Figure 3.5 Relative gene expression levels of Activin A, IL-5, Angiogenin and their 
receptors. These graphs represent the average relative gene expressions in two 
independent experiments. (INHBA: Activin A, ACVR1B: Activin A receptor 1B, IL5: 
Interleukin 5, IL5RA: Interleukin 5 receptor A, ANG: Angiogenin) 
 
3.4 Gene expression deregulations of cytokines and their receptors in human breast 
cancer tumors 
To determine how the gene expression of these cytokines and their receptors are 
changed in breast cancer tumors, we extracted total RNA from healthy and tumor frozen 
samples of 17 breast cancer patients. The levels of the gene expressions in tumor samples 
were compared to their healthy tissue sample counterparts. We have found that all three 
cytokines and their receptors were expressed in elevated levels in most of the tumor 
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samples compared to healthy tissue samples (Figure 3.6). Furthermore, we analyzed these 
results to see if we could find a correlation between the tumor grade and gene expression 
levels. However, we were not able to identify a correlation (Table 3.1). 
 
Figure 3.6 Deregulation of Activin A, IL-5, Angiogenin and their receptor gene 
expressions in breast cancer tumors. Gene expression levels were identified using qRT-
PCR after RNA extraction from frozen healthy and tumor tissue samples of 17 breast 
cancer patients. 
 
Table 3.1 Tumor grades and gene expression regulations. 
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3.5 Preventing the tumor promoting effect of CAFs using neutralizing antibodies 
After we showed that CAFs are able to promote cancer cell proliferation, this 
effect does not necessarily require cell-to-cell contact and it can be achieved through 
secretion of certain cytokines differently than normal fibroblasts, we started to wonder if 
we could prevent this by using specific neutralizing antibodies, so it will stop the 
downstream signaling pathways. For this purpose, we commercially obtained neutralizing 
antibodies against Activin A, IL5 and Angiogenin.  
 
3.5.1 Testing of neutralizing antibodies’ effectiveness 
To assess whether Activin A and Angiogenin neutralizing antibodies work 
efficiently we performed HUVEC tube formation assay and MDA-MB-231 wound 
healing assay with or without the presence of neutralizing antibodies. HUVEC cells have 
been shown to form tubes similar to vasculature when they are grown in Matrigel. 
However, when there is an anti-angiogenic factor like VEGF neutralizing antibody in the 
culture media they can no longer form these tubes. For this reason, we performed an 
experiment where we culture HUVEC cells in Matrigel with or without VEGF 
neutralizing antibody as positive and negative control. We tested the effectiveness of 
Angiogenin neutralizing antibody and compared the tube formation with controls. When 
we treated these cells with Angiogenin neutralizing antibody, we observed that HUVEC 
cells cannot form tubes and the number of nodes increase (Figure 3.7). This result was 
very similar to the effect of VEGF antibody, so we concluded that our antibody works 
efficiently.  
 
 
Figure 3.7 Effect of Angiogenin neutralizing antibody on HUVEC tube formation.  
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Similarly, to test the effectiveness of Activin A neutralizing antibody, we 
performed a wound healing assay. There are several studies showing that autocrine 
signaling of Activin A enhances the migratory capacity of MDA-MB-231 cells. Hence, 
we treated these cells with Activin A neutralizing antibody for 24 hours and observed 
wound healing activity. Compared to control, we observed a significant decrease in 
wound healing suggesting that the antibody works efficiently (Figure 3.8). 
 
 
Figure 3.8 Effect of Activin A neutralizing antibody on MDA-MB-231 wound healing. A. 
Microscopy images of 0 hour and 24 hours after the culture with or without Activin A 
neutralizing antibody. B. Quantification of MDA-MB-231 cells wound healing (n=3, 
p<0.05) 
 
3.5.2 Effect of Activin A, IL5 and Angiogenin neutralizing antibodies on the growth 
of MCF7 cells 
After we showed that our antibodies work effectively, we wanted to see their 
effect on the growth of MCF7 cells when they are co-cultured with CAFs. To determine 
whether these antibodies will be able to reverse the tumor promoting role of CAFs in co-
cultures, we checked luciferase activity of MCF7 cells after 72 hours of co-culture under 
the presence of each neutralizing antibody (1 µg). We compared these results with the 
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group where we didn’t treat the cells with any of those antibodies. Relative luciferase 
activity results showed that both Activin A and Angiogenin neutralizing antibodies were 
able to significantly inhibit the growth of MCF7 cells compared to CAF co-culture, 
whereas although we also observed a decrease when we used IL5 antibody, it was not 
significant (p=0.0507) (Figure 3.9). This result suggested that pro-tumorigenic role effect 
of CAFs are through secretion of cytokines and this can be significantly reversed with the 
use of targeted neutralizing antibodies. 
 
                                                      
Figure 3.9 Effect of neutralizing antibodies on MCF7 cell growth. Compared to CAF co-
culture without any antibodies, both Activin A and Angiogenin neutralizing antibody 
treatments resulted in significant decreases in relative luciferase activity of MCF7 cells 
after 72 hours co-culture (n=3, p<0.05). Similarly, IL5 antibody considerably lowered 
the cell growth. 
 
3.6 Effect of recombinantly produced cytokines on cancer cell growth in vitro 
To determine whether Activin A, IL5 and Angiogenin were sufficient to promote 
the growth of cancer cells in vitro, we transfected Hek293T cells with commercially 
obtained plasmids of these cytokines and produced flag tagged proteins. Since, all these 
three factors are secreted from cells, we expected to able to detect these proteins in the 
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culture media 72 hours after the transfection. After we collected the media and condition 
them, we used Western Blot using flag antibody to detect flag tagged proteins. Our results 
showed that the transfection was successful and Hek293T cells secreted these cytokines 
in abundant amounts. Later, we used these conditioned media to treat MCF7 and T47D 
cells for 72 hours without co-culturing them with CAFs. After 72 hours, these cells were 
collected, and their relative luciferase activities were compared to MCF7 and T47D alone 
conditions. Without CAFs, treatment of MCF7 (Figure 3.10A) and T47D (Figure 3.10B) 
cells with each of recombinantly produced Activin A, IL5 and ANG significantly 
increased their growth. This result suggested that the tumor promoting effect of CAFs in 
tumor stroma is achieved by the secretion of cytokines and presence of these proteins are 
sufficient to enhance tumor growth without the presence of CAFs. 
 
Figure 3.10 Effect of recombinantly produced cytokines on MCF7 and T47D cell growth. 
A. Relative luciferase activity of MCF7 cells 72 hours after the treatment of Activin A 
(p<0.005), IL5 (p<0.05) and Angiogenin (p=0.005). B. Relative luciferase activity of 
T47D cells 72 hours after the treatment of Activin A (p<0.05), IL5 (p<0.05) and 
Angiogenin (p=0.05). (n=3 for each condition) 
 
3.7 Effect of cytokines on cancer cell autophagy 
Autophagy has been reported to act as survival mechanism in established tumors 
and several studies have shown that it can also act as a chemotherapy resistance 
mechanism in tumors. Similarly, it helps cancer cells maintain their metabolic activities 
under stress conditions. Hence, we wanted to see whether Activin A, IL5 and Angiogenin 
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had any effect on cancer cell autophagy. For this reason, we treated MCF7 and T47D 
cells with recombinantly produced cytokines for 12 and 24 hours. We used LC3-I to LC3-
II conversion to observe autophagic activation. We were able to show that these cytokines 
induced autophagy especially in T47D cells after 24 hours (Figure 3.11). This result 
implies that CAFs may induce tumor growth trough cytokine secretion which may alter 
autophagic activity of cancer cells. 
 
 
Figure 3.11 Effects of recombinant proteins on autophagic activity of MCF7 and T47D 
cells. 12 and 24 hours after the treatment of these cells with recombinant proteins, their 
autophagic activities were measured LC3-II/I ratio. 
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4. DISCUSSION 
Cancer is one of the biggest challenges that the scientists are facing today. Despite 
extensive research and funding, unfortunately there is still variance between experimental 
and clinical outcomes. Although there are many approaches available to cure cancer, most 
of them target only cancer cells. However, we now know that these cancer cells reside in 
a microenvironment called tumor stroma and there is a constant crosstalk between cancer 
cells and neighboring cells. Thus, understanding the tumor stroma, its components, 
interactions, and crosstalk of cancer cells and stromal cells may have a crucial importance 
for treating cancer. Tumor stroma has been shown to be composed of different cell types 
and studies suggest that these cells can be recruited and manipulated by malignant cells 
to support tumor growth and metastasis. In addition, stromal cells can modify and 
transform the connective tissue so that the microenvironment becomes a permissive one 
for cancer progression. Although normal tissue stroma is essential for tissue homeostasis, 
even minor changes leading to tumor stroma may cause dramatic alterations. The tumor 
stroma basically consists of a heterogeneous population of fibroblasts, immune cells, 
vasculature, pericytes, endothelial cells and ECM. In this study, we focused on cancer 
associated fibroblasts which is one of the major components of tumor stroma. CAFs have 
been shown to have a tumor promoting role due to epigenetic and possibly genetic 
differences in their genome. In many co-culture experiments, results showed that CAFs 
enhance the growth of cancer cells when they are co-cultured together. Additionally, 
differently than fibroblasts and normal fibroblasts, CAFs proliferate robustly, gain 
enhanced migratory capacity and increased level of secretion.  
In this study, we obtained fibroblasts and CAFs from healthy and tumor samples 
of breast cancer patients. First, we co-cultured MCF7 and T47D cells with either 
fibroblasts or CAFs to determine whether CAFs could enhance the proliferation of breast 
cancer cell lines in vitro compared to normal conditions and fibroblast co-culture. Our 
luciferase activity results after 72 hours of co-culture revealed that CAFs can increase the 
growth of MCF7 and T47D cells. Similarly, we confirmed this result with FACS analysis 
and microscopy images. Furthermore, to identify whether this tumor promoting effect of 
CAFs was due to cell-to-cell contact, we provided a physical distance in co-culture 
conditions which will allow them to communicate only through secreted molecules. Our 
results indicated that, even without cell-to-cell contact, CAFs are still able to enhance 
cancer cell growth through cytokine secretion. After 72 hours of co-culture with either 
fibroblasts or CAFs, we used RayBiotech cytokine array and we were able to identify 
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three cytokines (Activin A, IL5 and Angiogenin) that were present in higher amounts in 
CAF co-culture media. Today, we know that neighboring cells have a continuous 
communication and there is a crosstalk between cancer cells and stromal cells. To 
determine which cells provide these three cytokines that are present in the media, we 
separately collected cancer cells and CAFs and checked their expression levels. qRT-PCR 
results suggested that CAFs are the main source of Activin A, MCF7 cells are the main 
source of IL5 and they contribute similarly to the secretion of Angiogenin. Additionally, 
we wanted to see if the expressions of the cytokines were altered in human breast cancer 
tumor samples. Compared to healthy tissues, we observed higher expression of the 
cytokines in tumor samples. 
Targeting tumor stroma and the crosstalk between cancer cells and CAFs may be 
used as another approach in treating cancer. An application of this can be the use of 
neutralizing antibodies which will block the communication and downstream signaling. 
For this reason, we co-cultured MCF7 cells with CAFs for 72 hours and treated them with 
neutralizing antibodies of Activin A, IL5 and Angiogenin. Especially Activin A and 
Angiogenin antibodies significantly reduced the growth of cancer cells. Given that most 
of Activin A was provided by CAFs in co-culture experiments, this result shows the 
potential of neutralizing antibodies for blocking the communication and the tumor 
promoting role of CAFs. On the other hand, we used recombinantly produced cytokines 
which we obtained from transfected Hek293T cell media. After 72 hours of treatment of 
both MCF7 and T47D cells with recombinant cytokines resulted in a significant 
enhancement in the growth of these cells. 
According to recent studies, cancer cells develop several mechanisms to 
overcome stress conditions. Autophagy has also been proposed as one of these 
mechanisms to promote tumor growth by maintaining the metabolic activities and drug 
resistance in established tumors. To assess the autophagic activity in MCF7 and T47D 
cells, we treated them with recombinant cytokines for 12 and 24 hours. Our results 
suggested that, especially in T47D cells, cytokines induced autophagy. 
A tumor cannot develop without the parallel expansion of tumor stroma. Although 
we still don’t know the exact role of tumor stroma in tumorigenesis and cancer 
progression, the available evidences suggest that cancer associated fibroblasts have a 
crucial role. In this study we present that CAFs may have a role in promoting cancer 
through cytokine secretion and they can be defined as potential targets for anticancer 
therapy.  
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